Brought to you by:
FORS-powered LumiGuide 3D imaging technology is rolled out at specialized centers in U.S. and Europe
Andres Schanzer, MD, has hailed it “one of the most exciting changes” seen in imaging during the course of his career. Philips’ LumiGuide “human GPS” technology—which uses light reflected along an optical fiber inside a guidewire to generate three-dimensional (3D),…
A proposal to save vascular surgery
In response to recent articles in the lay press suggesting vascular surgeons were performing unnecessary procedures, Vascular Specialist medical editor, Malachi Sheahan, has asked me to write an editorial based on a talk I presented at the 2023 VEITHsymposium. At…
Could metformin be first-ever medical treatment that is effective at managing aneurysm disease?
There is a global interest in assessing whether metformin, which has a long track record of safety and efficacy, is relatively inexpensive and is taken by millions of people every day for type-2 diabetes, has an effect on the progression…
‘There is no reliable way to measure carotid stenosis—methods have changed and tend to overestimate the degree of narrowing’
The recent move to expand Medicare coverage of carotid stenting formed the basis of a recent debate over the wisdom of the decision taken by the Centers for Medicare & Medicaid Services (CMS). Two heavyweights in the stroke arena went…
Changing course: The natural history of tibial claudication comes under scrutiny as interventions for ‘relatively benign’ disease trend upward
In the end, reflected Michael S. Conte, MD, “it’s not the evidence.” The leading vascular surgeon and peripheral arterial disease (PAD) expert made the bold statement during the recent 2023 VEITHsymposium (Nov. 14–18) as he pointedly asked a room full…
Intravenous anesthesia delivery during varicose vein treatment proves safe and reduces pain scores, researcher reports
A new intravenous anesthesia delivery technique used during endothermal ablation for varicose veins demonstrated comparatively low pain scores according to first-in-human (FIH) data recently presented at the 2023 VEITHsymposium. The investigational Solutio catheter (MedVasc), which contains both a bent needle…
TRANSCEND 36-month data “continue to demonstrate safe and effective performance” of SurVeil DCB
Peter Schneider (University of California San Francisco, San Francisco, USA) recently presented 36-month data from Surmodics’ TRANSCEND clinical trial at the VEITHsymposium 2023 (14–18 November, New York, USA). The TRANSCEND trial is a prospective, multicentre, single-blind randomised controlled trial to…
Twelve-month first-in-human data from Xeltis’ aXess haemodialysis vascular conduit trial presented at VEITHsymposium 2023
Xeltis has announced “highly encouraging” 12-month results from its first-in-human (FIH) aXess vascular conduit trial. The data were presented by Frans Moll (University Medical Center Utrecht, Utrecht, The Netherlands) at this year’s VEITHsymposium (14–18 November, New York, USA). At 12…
Randomized trial set to elucidate value of image fusion technology for aortic repair
An ongoing UK National Institute for Health and Care Research (NIHR)-funded randomized controlled trial seeks to illuminate the value of an image fusion guidance technology for endovascular aortic repair. In a presentation on the trial at this year’s VEITHsymposium…
Two-year SWING data ‘continue to show promise’ for sirolimus DCB in treating BTK disease
Two-year data from the SWING trial, a first-in-human study of the safety and performance of the Sundance sirolimus drug-coated balloon (DCB; Surmodics), have been presented at this year’s VEITHsymposium (Nov. 14–18) in New York City. The SWING trial is a…